Friday 6 November 2026 Export CVRX’s income statement to Excel — free account

CVRx, Inc.

CVRX Healthcare Medical Devices

CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024.

Revenue: −5.84%
EPS: −6.12%
Free cash flow: −9.91%
Total debt: +18.6%

Quarter to September 2026, against a year earlier

0.85 0.62 −42.18%

Follow CVRX

Alert me

Market cap: $39.2M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 4/9
Altman Z: −6.26
Beneish M: −3.03
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.38

Sold, $m 0.13

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	2	—	—	—	—	—	1	—	—	—
Sell	—	—	—	5	—	—	—	—	1	—	—	—

Insider Ownership 40.54%

Capital & Financial Ratios $m

Size

Market Cap 39.16

Revenue ttm 60.33

Net income ttm (53.26)

Free cash flow ttm (42.04)

Net debt Q (0.09)

Valuation

P/E 0.00

Forward P/E (0.70)

Price / sales 0.65

Forward P/S Powerpack

Price / FCF 0.00

Price / book 2.84

Financial health

Current ratio Q 6.80

Debt / equity Q 4.24

Interest coverage Q (8.12)

Growth

Revenue growth Q −5.84%

Operating income growth Q −6.33%

EPS, this year +1.14%

EPS, next year A +6.17%

Revenue, next year A +3.88%

EPS, past 5 yrs —

EPS, next 5 yrs A +4.89%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.19%

10-year low 10-year high

P/B against its own 10 years 38.72%

10-year low 10-year high

EV/Sales against its own 10 years 2.22%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	91	106	76	59
Receivables	8	9	11	10
Inventory	11	12	12	14
Other	—	—	—	—
	112	130	102	85

	2023	2024	2025	Q'26
Payables	2	3	4	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	8	11	13	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	56.40%	36.11%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	1.37%	(28.85%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.52 Actual −0.53

−0.55 −0.51 −0.47 −0.44 −0.40

Q3 FY25 Beat +0.01

Q4 FY25 Miss −0.04

Q1 FY26 Beat +0.01

Q2 FY26 Miss −0.01

Q3 FY26 — Nov 5

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.50	−0.49	Beat by 0.01
Q4 FY25	−0.42	−0.46	Miss by 0.04
Q1 FY26	−0.51	−0.50	Beat by 0.01
Q2 FY26	−0.52	−0.53	Miss by 0.01
Q3 FY26	−0.49	—	Reports 5 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.50)	(0.53)	(0.52)	—	—
’25	(0.53)	(0.57)	(0.49)	(0.46)	(2.04)
’24	(1.04)	(0.65)	(0.57)	(0.43)	(2.65)
’23	(0.55)	(0.56)	(0.43)	(0.44)	(1.99)
’22	(0.49)	(0.54)	(0.48)	(0.51)	(2.02)
’21	(23.92)	(48.48)	(0.30)	(0.52)	(4.16)
’20	(0.19)	(10.19)	(8.96)	—	(36.46)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	15	16	14	—	—
’25	12	14	15	16	57
’24	11	12	13	15	51
’23	8	10	11	11	39
’22	4	5	6	7	22
’21	3	3	3	4	13
’20	2	1	1	—	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(9)	(11)	—	—
’25	(13)	(8)	(10)	(10)	(40)
’24	(11)	(10)	(10)	(8)	(39)
’23	(10)	(13)	(8)	(8)	(39)
’22	(11)	(10)	(11)	(11)	(43)
’21	(5)	(6)	(9)	(7)	(28)
’20	(5)	(7)	(5)	(4)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(9)	(11)	—	—
’25	(13)	(8)	(10)	(10)	(41)
’24	(12)	(10)	(10)	(8)	(41)
’23	(10)	(13)	(8)	(8)	(40)
’22	(11)	(10)	(11)	(11)	(43)
’21	(5)	(7)	(9)	(8)	(29)
’20	(5)	(7)	(5)	(4)	(16)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	6	6	13	22	39	51	57	60		+44.4%	59	66	77	+10.9%
	Gross margin, %	—	—	—	72.21	76.21	72.08	77.75	84.08	83.75	85.33	86.90		+13.1 pt	Powerpack CVRx, Inc.’s next three years, line by line Analysts expect revenue to grow 10.9% a year to 2028 — slower than the 44.4% of the last 6 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	—	(15)	(14)	(43)	(41)	(41)	(60)	(53)	(53)		+24.2%
	EBT margin, %	—	—	—	(232.70)	(231.69)	(329.76)	(183.89)	(104.47)	(116.80)	(94.13)	(88.29)		+138.6 pt
	Net income	—	0	—	(15)	(14)	(43)	(41)	(41)	(60)	(53)	(53)		n/m
Per share, $
Per share, $	Revenue	—	—	—	0.32	15.64	1.26	1.09	1.89	2.27	2.17	2.21		+37.3%
	Earnings	—	—	—	(0.76)	(36.46)	(4.16)	(2.02)	(1.99)	(2.65)	(2.04)	(2.01)		+17.9%
	Cash flow	—	—	—	(0.66)	(41.59)	(2.68)	(2.08)	(1.88)	(1.73)	(1.54)	(1.53)		+15.1%
	Capex	—	—	—	0.00	(0.80)	(0.11)	(0.03)	(0.03)	(0.06)	(0.02)	(0.01)		n/m
	Free cash flow	—	—	—	(0.66)	(42.40)	(2.79)	(2.11)	(1.91)	(1.79)	(1.56)	(1.54)		+15.4%
	Book value	—	—	—	(14.46)	94.95	14.09	5.32	3.66	3.14	1.51	0.51		n/m
	Shares, m	—	—	—	19	0	10	21	21	23	26	27		+5.2%
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	1.25	1.25	9.72	17.12	16.10	5.58	3.27	0.65		7.8
	P/B	—	—	—	0.00	0.00	0.87	3.52	8.33	4.03	4.71	2.84		3.1
	EV/Sales	—	—	—	(2.12)	(2.12)	0.32	12.84	14.63	4.54	2.87	0.70		4.4
	EV/FCF	—	—	—	0.81	0.81	(0.14)	(6.65)	(14.51)	(5.75)	(3.98)	(1.01)		(4.2)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(13)	(16)	(28)	(43)	(39)	(39)	(40)	(42)		+21.0%
	Capex	—	—	—	0	0	(1)	(1)	(1)	(1)	(1)	0		+32.7%
	Free cash flow	—	—	—	(13)	(16)	(29)	(43)	(40)	(41)	(41)	(42)		+21.3%
Balance, $m
Balance, $m	Working capital	—	—	—	20	56	145	115	104	119	88	73		+27.8%
	Net debt	—	—	—	273	(40)	(142)	(99)	(61)	(57)	(26)	0		n/m
	Shareholders’ equity	—	—	—	(279)	37	146	109	76	71	39	14		n/m
Returns, %
Returns, %	ROA	—	—	—	(100.64)	(30.52)	(39.64)	(29.86)	(34.31)	(48.23)	(44.76)	(53.55)		+55.9 pt
	ROIC	—	—	—	0.00	0.00	(417.55)	(273.09)	(184.52)	(258.29)	(244.03)	(224.98)		(244.0) pt
	ROE	—	—	—	5.12	5.01	58.50	(32.47)	(44.51)	(81.58)	(96.59)	(172.17)		(101.7) pt
People
People	Employees	—	—	—	—	63	109	160	200	206	223	—		+28.8%
	Revenue/emp, $m	—	—	—	0.00	0.10	0.12	0.14	0.20	0.25	0.25	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MYO Myomo, Inc.	$47.1M	— (loss-making)	— (loss-making)	+21.26% (above 0%: growing)	n/m	+80.02% (above 0%: growing)	72.13%	(19.26%)	Compare
MDAI Spectral AI, Inc.	$44.4M	— (loss-making)	— (loss-making)	−30.42% (below 0%: shrinking)	n/m	−21.86% (below 0%: shrinking)	31.58%	(122.70%)	Compare
XTNT Xtant Medical Holdings, Inc.	$42.1M	— (loss-making)	— (loss-making)	−34.96% (below 0%: shrinking)	n/m	−881.96% (below 0%: shrinking)	57.88%	(39.81%)	Compare
CVRX CVRx, Inc.	$39.2M	— (loss-making)	— (loss-making)	−5.84% (below 0%: shrinking)	n/m	−9.91% (below 0%: shrinking)	86.74%	(94.31%)
TELA TELA Bio, Inc.	$35.2M	— (loss-making)	— (loss-making)	−4.49% (below 0%: shrinking)	n/m	−17.72% (below 0%: shrinking)	72.77%	(48.12%)	Compare
ELUT Elutia Inc.	$33.3M	0.6×	— (loss-making)	−11.65% (below 0%: shrinking)	n/m	−2.52% (below 0%: shrinking)	59.62%	(327.85%)	Compare
RPID Rapid Micro Biosystems, Inc.	$31.1M	— (loss-making)	— (loss-making)	+10.91% (above 0%: growing)	n/m	−23.97% (below 0%: shrinking)	15.05%	(152.99%)	Compare
NSPR InspireMD, Inc.	$29.7M	— (loss-making)	— (loss-making)	−0.39% (below 0%: shrinking)	n/m	−26.00% (below 0%: shrinking)	(43.70%)	(815.64%)	Compare
SNWV Sanuwave Health Inc.	$19.4M	1.3×	— (loss-making)	−3.13% (below 0%: shrinking)	n/m	+86.75% (above 0%: growing)	76.23%	(2.88%)	Compare
Median of peers	$34.2M	—	—	−3.81%	—	−19.79%	58.75%	(85.41%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 20 April 2026

Ownership

Directors and executive officers, together 16.60%

Johnson & Johnson 15.20%

New Enterprise Associates 7.70%

Kirk Nielsen 7.60%

Vensana Capital I, L.P. 6.50%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

CVRx, Inc. (CVRX) Latest News

6 Nov

Impact 4 · 11:03 AM · The Motley Fool transcript

CVRx (CVRX) Q3 2026 Earnings Call Transcript

Impact 3 · 2:23 AM · GuruFocus.com

CVRx Inc (CVRX) Q3 2026 Earnings Call Highlights: Revenue Misses Guidance as Reimbursement ...

5 Nov

Impact 3 · 4:05 PM · GlobeNewswire

CVRx Reports Third Quarter 2026 Financial and Operating Results

29 Sep

Impact 4 · 4:30 PM · GlobeNewswire

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

21 Sep

Impact 4 · 4:07 PM · GlobeNewswire

CVRx Appoints John Landry as Chief Financial Officer

28 Aug

Impact 3 · 11:39 AM

CVRx Secures Devoted Health Coverage for Barostim Therapy

24 Aug

Impact 4 · 8:30 AM

Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer

Impact 3 · 8:30 AM

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

13 Aug

Impact 4 · 3:02 AM · MarketBeat

CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches

Impact 3 · 6:15 PM · The Motley Fool transcript

CVRx (CVRX) Q2 2026 Earnings Call Transcript

7 Aug

Impact 3 · 8:30 AM · Moby

CVRx, Inc. Q2 2026 Earnings Call Summary

Impact 3 · 1:08 AM transcript

CVRx Inc (CVRX) (Q2 2026) Earnings Call Highlights: Sales Execution Challenges Offset Strong ...

6 Aug

Impact 3 · 10:35 PM

CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates

Impact 3 · 9:03 PM · MarketBeat transcript

CVRx Q2 Earnings Call Highlights

Impact 3 · 8:00 PM

Compared to Estimates, CVRx (CVRX) Q2 Earnings: A Look at Key Metrics

Impact 3 · 4:05 PM

CVRx Reports Second Quarter 2026 Financial and Operating Results

18 May

Impact 4 · 12:32 PM · Zacks

CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy

15 May

Impact 3 · 6:39 AM · Simply Wall St.

Analysts Have Made A Financial Statement On CVRx, Inc.'s (NASDAQ:CVRX) First-Quarter Report

14 May

Impact 4 · 8:00 AM · GlobeNewswire

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

13 May

Impact 3 · 9:35 AM · Zacks

Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)

12 May

Impact 4 · 8:30 AM · Moby transcript

CVRx, Inc. Q1 2026 Earnings Call Summary

Impact 4 · 3:06 AM · GuruFocus.com

CVRx Inc (CVRX) Q1 2026 Earnings Call Highlights: Strong U.S. Growth and Market Expansion Potential

11 May

Impact 4 · 7:05 PM · MarketBeat

CVRx Q1 Earnings Call Highlights

Impact 4 · 4:05 PM · GlobeNewswire

CVRx Reports First Quarter 2026 Financial and Operating Results

Impact 3 · 6:05 PM · Zacks

CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates

4 May

Impact 4 · 4:30 PM · GlobeNewswire

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

13 Apr

Impact 4 · 8:00 AM · GlobeNewswire

CVRx Reports Preliminary First Quarter 2026 Financial Results

2 Mar

Impact 4 · 8:30 AM · GlobeNewswireMarketBeatGuruFocus.com

CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

15 Feb

Impact 4 · 8:01 PM · GuruFocus.com

CVRx Inc (CVRX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amid ...

Impact 4 · 8:24 AM · Simply Wall St.

Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results

CVRx, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

CVRx, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 20 April 2026

Ownership

CVRx, Inc. (CVRX) Latest News

6 Nov

5 Nov

29 Sep

21 Sep

28 Aug

24 Aug

13 Aug

7 Aug

6 Aug

18 May

15 May

14 May

13 May

12 May

11 May

4 May

13 Apr

2 Mar

15 Feb

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

CVRx, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 20 April 2026

Ownership

CVRx, Inc. (CVRX) Latest News

6 Nov

5 Nov

29 Sep

21 Sep

28 Aug

24 Aug

13 Aug

7 Aug

6 Aug

18 May

15 May

14 May

13 May

12 May

11 May

4 May

13 Apr

2 Mar

15 Feb

Stockrow Weekly